[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100129030":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":23,"locations":31,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Barts & The London NHS Trust","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Diabetes mellitus, renal impairment",null,"Patients with both diabetes mellitus and eGFR \\\u003C60 ml\u002Fmin",[13,17,20],{"name":14,"affiliation":15,"role":16},"AKHIL KAPUR","CONSULTANT CARDIOLOGIST AND HONORARY SENIOR LECTURER, BARTS AND THE LONDON NHS TRUST","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":19,"role":16},"KATIE QURESHI","Clinical Research Fellow\u002FSpecialist Registrar, Barts and The London NHS Trust",{"name":21,"affiliation":22,"role":16},"MAGDI YAQOOB","PROFESSOR AND CONSULTANT NEPHROLOGIST, HEAD DEPARTMENT OF EXPERIMENTAL MEDICINE AND NEPHROLOGY",[24,28],{"name":14,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","0208 983 2413","akhil.kapur@bartsandthelondon.nhs.uk",{"name":18,"role":25,"phone":29,"phoneExt":10,"email":30},"0208 983 2477","katie.qureshi@bartsandthelondon.nhs.uk",[32],{"facility":33,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"The London Chest Hospital","RECRUITING","London","E2 9JX","United Kingdom","UK",{"type":40,"coordinates":41},"Point",[42,43],-0.12574,51.50853,{"lat":43,"lon":42},[46,47,48,49,51],{"name":14,"role":25,"phone":26,"phoneExt":10,"email":27},{"name":18,"role":25,"phone":29,"phoneExt":10,"email":30},{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"name":18,"role":50,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":21,"role":16,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100129030","development-of-a-biomarker-panel-for-the-earlier-prediction-of-acute-kidney-injury-in-patients-with-diabetes-100129030",false,"NCT00948116","Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes","Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing Coronary Revascularisation","BIOMARKERS","Inclusion Criteria:\n\n1. Age \\> 18 years, known diabetes mellitus or BM on arrival consistent with probable diagnosis of diabetes, eGFR \\\u003C60 ml\u002Fmin\n2. Undergoing a PCI procedure\n3. Agrees to the additional collection of blood and urine samples as outlined above\n4. Agrees to access of their clinical records for the collection of relevant medical data\n5. No history or signs of drug abuse\n6. Able to understand and sign the written Informed Consent Form\n7. Able and willing to follow the Protocol requirements\n\nExclusion Criteria:\n\n1. Cardiogenic shock\n2. Pregnancy\n3. Patient on renal replacement therapy (haemodialysis\u002FCAPD\u002Frenal transplant)\n4. Known clinically significant infection such as HIV, Hepatitis or TB\n5. Any patient determined not able to make a reasoned, informed consent prior to the planned interventional procedure","ALL","18 Years",{"count":65,"type":66},250,"ESTIMATED","OBSERVATIONAL","Patients living with diabetes mellitus have double the risk of kidney failure compared to patients without diabetes following use of dye in many x-rays and procedures to diagnose and treat narrowing of the arteries (blood vessels) in the heart that can lead to angina or a heart attack. Heart disease is the commonest cause of death in patients with diabetes. People with diabetes are more likely to need these tests\u002Ftreatments. By identifying those at greater risk of kidney complications we may be able to make these tests\u002Ftreatments safer and offer them to more patients with diabetes.",[70,71],"Diabetes Mellitus","Renal Impairment",[73,71,74,75,76],"Diabetes mellitus","Acute Kidney Injury","Coronary revascularisation","eGFR \u003C60ml\u002Fmin","2024-12-05",{"date":79,"type":80},"2024-12-10","ACTUAL",{"date":82,"type":80},"2009-06-24",{"date":84,"type":66},"2025-12-31",{"name":5,"class":6},1]